Kyoto Institute Defends Yamanaka Against Short-Seller Allegations of Image Duplication

Key points

• Gotham City Research released a report on August 7, 2026, alleging image manipulation in ten papers authored or co-authored by Shinya Yamanaka between 2000 and 2020.
• CiRA, Yamanaka's institute, stated that questioning his integrity without sufficient evidence is 'completely unacceptable' and that the allegations disregard the specific facts of each case.
• Yamanaka was the first or corresponding author on only three of the ten flagged papers; for four others, he was a coauthor only because he provided research materials like cells or mice.
• CiRA noted that issues in two of the papers had already been investigated and resolved, with one paper corrected in 2008 and another cleared by journal editors in 2014.
• Gotham City Research, founded by Daniel Yu, has shorted the stocks of Sumitomo Chemical and Sumitomo Pharmaceutical, both of which have funded CiRA.
• The report includes two papers on which Yamanaka was not a coauthor; one was retracted in 2018 due to fabrication by a colleague, Kohei Yamamizu, whom Yamanaka previously acknowledged responsibility for not preventing.

Background

This controversy follows earlier incidents involving Kyoto University and CiRA, including the 2018 retraction of a paper by Kohei Yamamizu for data fabrication, which led to his dismissal and penalties for Yamanaka. The current dispute arises in the context of Japan's conditional approval of Amchepry, a Parkinson's disease treatment based on reprogrammed stem cells, which has raised concerns among some researchers about the limited patient testing involved. The archive also notes broader patterns of scientific misconduct investigations, such as the decade-long retraction of a breast cancer study, highlighting the ongoing scrutiny of data integrity in biomedical research.

Why it matters

The allegations challenge the credibility of a foundational figure in stem cell research and could impact public trust in regenerative medicine therapies. The involvement of a short-selling firm introduces financial motives into scientific integrity debates, potentially influencing stock markets and institutional funding. CiRA's defense emphasizes the importance of distinguishing between routine corrections and systematic misconduct, while the dispute underscores the need for transparent institutional responses to external critiques.

What to watch

CiRA stated that no ongoing institutional probes are currently underway, and they have not communicated with Gotham City Research. The institute expects to address the remaining concerns through standard review processes, particularly for the 2020 paper under review by former CiRA director Jun Takahashi. Gotham City Research may continue to publicize its findings, potentially affecting the stock prices of Sumitomo Chemical and Sumitomo Pharmaceutical. Yamanaka has not yet issued a direct public statement, with CiRA handling communications on his behalf.